# US 2013/0253014 A1 · Cyclodextrin-Based Microemulsions, and Dermatological Uses Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0253014 A1
- Document ID: US20130253014A1
- Status: Published application
- Kind: A1
- Application number: 13/803,280
- Filed: 2013-03-14
- Published: 2013-09-26
- Earliest claimed: 2012-03-22
- Assignees: Precision Dermatology, Inc.
- Applicants: Precision Dermatology, Inc.
- Inventors: Mark W. Trumbore; Pinaki Ranjan Majhi; Dinen Divyang Shah
- Web page: https://patentgrep.com/patent/US20130253014A1

## CPC

- A61K 47/40: Cyclodextrins; Derivatives thereof
- A61K 8/068: {Microemulsions}
- A61K 8/39: Derivatives containing from 2 to 10 oxyalkylene groups
- A61K 8/671: {Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal}
- A61K 8/738: {Cyclodextrins}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 31/07: Retinol compounds, e.g. vitamin A (retinoic acids A61K31/203)
- A61K 31/455: Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/16: Emollients or protectives, e.g. against radiation
- A61Q 19/08: Anti-ageing preparations
- A61K 8/92: Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K 33/08: Oxides; Hydroxides
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

Described herein are cyclodextrin-stabilized microemulsion systems useful for increasing the solubility, stability, bioavailability, or safety of an active agent for delivery to the skin. The microemulsions may reduce the occurrence of skin irritation or odor upon application.

## Claims

### Claim 1

A microemulsion, consisting essentially of: an aqueous phase; a first surfactant; and a second surfactant, wherein the first surfactant is a cyclodextrin or a derivative of a cyclodextrin.

### Claim 2 (depends on 1)

The microemulsion of claim 1, wherein the aqueous phase is present in an amount from about 75% to about 95% by weight of the microemulsion.

### Claim 3 (depends on 1)

The microemulsion of claim 1, wherein the aqueous phase comprises a moisturizer or emollient.

### Claim 4 (depends on 3)

The microemulsion of claim 3, wherein the moisturizer or emollient is selected from the group consisting of panthenol, allantoin, sodium hyaluraonate, pentylene glycol, and combinations/mixtures thereof.

### Claim 5 (depends on 3)

The microemulsion of claim 3, wherein the moisturizer or emollient is present in an amount from about 0.8% to about 2.3% by weight of the aqueous phase.

### Claim 6 (depends on 1)

The microemulsion of claim 1, wherein the aqueous phase comprises an anti-inflammatory agent.

### Claim 7 (depends on 6)

The microemulsion of claim 6, wherein the anti-inflammatory agent is niacinamide.

### Claim 8 (depends on 6)

The microemulsion of claim 6, wherein the anti-inflammatory agent is present in an amount from about 0.5% to about 2% by weight of the aqueous phase.

### Claim 9 (depends on 1)

The microemulsion of claim 1, wherein the aqueous phase comprises an antioxidant or preservative.

### Claim 10 (depends on 9)

The microemulsion of claim 9, wherein the antioxidant or preservative is selected from the group consisting of potassium sorbate, sodium benzoate, disodium EDTA, and combinations/mixtures thereof.

### Claim 11 (depends on 9)

The microemulsion of claim 9, wherein the antioxidant or preservative is present in an amount from about 0.2% to about 0.6% by weight of the aqueous phase.

### Claim 12 (depends on 1)

The microemulsion of claim 1, wherein the aqueous phase comprises a pH adjuster.

### Claim 13 (depends on 12)

The microemulsion of claim 12, wherein the pH adjuster is sodium hydroxide.

### Claim 14 (depends on 12)

The microemulsion of claim 12, wherein the pH adjuster is present in an amount from about 0.02% to about 0.1% by weight of the aqueous phase.

### Claim 15 (depends on 1)

The microemulsion of claim 1, wherein the first surfactant is present in an amount from about 1% to about 8% by weight of the microemulsion.

### Claim 16 (depends on 1)

The microemulsion of claim 1, wherein the first surfactant is hydroxypropyl α-cyclodextrin, hydroxypropyl β-cyclodextrin, or hydroxypropyl γ-cyclodextrin.

### Claim 17 (depends on 1)

The microemulsion of claim 1, wherein the first surfactant is hydroxypropyl β-cyclodextrin.

### Claim 18 (depends on 1)

The microemulsion of claim 1, wherein the second surfactant is present in an amount from about 4% to about 22% by weight of the microemulsion.

### Claim 19 (depends on 1)

The microemulsion of claim 1, wherein the second surfactant comprises caprylocaproyl macrogol-8 glycerides or caprylocaproyl polyoxyl-8 glycerides.

### Claim 20 (depends on 1)

The microemulsion of claim 1, wherein the microemulsion consists essentially of:
water, in an amount of about 80% by weight of the microemulsion;
hydroxypropyl β-cyclodextrin, in an amount of about 5% by weight of the microemulsion; and
caprylocaproyl macrogol-8 glycerides or caprylocaproyl polyoxyl-8 glycerides, in an amount of about 15% by weight of the microemulsion.

### Claim 21 (depends on 1)

The microemulsion of claim 1, wherein the microemulsion consists essentially of:
water, in an amount of about 90% by weight of the microemulsion;
hydroxypropyl β-cyclodextrin, in an amount of about 3% by weight of the microemulsion; and
caprylocaproyl macrogol-8 glycerides or caprylocaproyl polyoxyl-8 glycerides, in an amount of about 7% by weight of the microemulsion.

### Claim 22 (depends on 1)

A method of making a microemulsion of claim 1, comprising the step of combining the aqueous phase, the first surfactant, and the second surfactant.
